Maternal and fetal healthcare in India is facing a major revolution. Recently, researchers from IIT Bombay and ICMR-NIRWoH developed a lab-grown model. This indigenous placenta-on-chip technology replicates the maternal-fetal interface in a laboratory setting. Historically, evaluating drug safety during pregnancy has remained incredibly difficult. Consequently, clinicians struggle to prescribe essential medications. Fortunately, this innovative platform successfully bridges this clinical gap.

The Challenge of Maternal-Fetal Research

The human placenta functions as a dynamic gatekeeper during gestation. Specifically, it regulates the critical exchange of oxygen, nutrients, hormones, and waste products between mother and fetus. In addition, it protects the developing baby from harmful external elements. Despite its vital clinical importance, the placenta remains one of the least understood human organs. This knowledge deficit occurs because direct clinical experimentation on pregnant women carries heavy ethical and practical limitations. Consequently, pharmaceutical companies face severe challenges when proving whether new drugs are safe for pregnant patients. Traditional animal models, such as pregnant mice, fail to provide accurate predictive data. This failure happens because human and animal placentas exhibit vastly different structural and physiological properties. As a result, pregnant women must often endure untreated illnesses or take under-researched medications. Therefore, medical researchers desperately need human-relevant models to run safe pre-clinical trials. To resolve this critical issue, the collaborative Indian research team developed an advanced microengineered model that mimics human physiology. Ultimately, this breakthrough provides a safer and highly reliable testing ground for maternal therapies. This technology promises to change the landscape of fetal research in the country.

Understanding Placenta-on-Chip Technology

How does this innovative placenta-on-chip technology actually operate? The newly developed platform features a compact, two-chamber device that replicates the maternal-fetal barrier. Within this microengineered device, researchers grow human placental cells and human blood vessel cells on opposite sides of a porous membrane. Furthermore, this unique spatial arrangement closely mimics the natural cell-to-cell interactions found in a real pregnancy. Unlike older and more complex organ-on-chip platforms, this Indian design avoids sophisticated, high-maintenance microfluidic machinery. Instead, the team utilized rigid acrylic components to manufacture a simple yet robust testing chamber. This material choice prevents the leakage and drug adsorption issues often associated with traditional polydimethylsiloxane models. Consequently, laboratories can easily adopt and run this device without investing in expensive specialized infrastructure. Moreover, this system operates under controlled laboratory conditions while simulating dynamic blood flow and realistic mechanical stresses. Thus, researchers can observe how different substances cross the placental barrier in real-time. By providing a scalable, user-friendly design, this platform allows scientists to perform high-throughput screening of various chemicals. Consequently, it represents a massive and highly practical leap forward for biomedical laboratories nationwide.

Key Replicated Functions and Biological Validation

Biomedical validation of the platform led to remarkable results. Specifically, Professor Deepak Modi's research group at ICMR-NIRWoH validated the device. They proved that the lab-grown model successfully reproduces critical human placental functions. For instance, the system actively secretes essential pregnancy hormones like human chorionic gonadotropin. Additionally, it accurately demonstrates selective barrier functions by allowing beneficial nutrients to pass while blocking toxic agents. During rigorous validation trials, the device successfully transported glucose and cleared waste products like urea. This behavior mirrors the metabolic activity of a healthy human placenta. Furthermore, the scientists tested the system's response under hyperglycemic conditions. Interestingly, the model successfully simulated gestational diabetes, exhibiting the classic pathophysiological changes seen in diabetic pregnancies. Because this device recreates disease-specific environments, doctors can study how high blood sugar impacts the fetus. Therefore, this platform serves as an invaluable tool for understanding complex pregnancy disorders. By proving its biological accuracy, the researchers showed that this placenta-on-chip technology can reliably replace animal experimentation in many preclinical contexts. As a result, this indigenous platform offers unprecedented clinical opportunities. Consequently, this breakthrough will transform maternal clinical care.

Clinical Implications for Drug Safety and Pharmacy

The clinical implications of this indigenous device are vast, particularly for pharmacology and maternal medicine. Currently, pregnant women face severe therapeutic disadvantages because of historical clinical trial exclusions. Consequently, many essential medications carry labels warning against use during pregnancy. This caution arises from safety concerns rather than proven harmful effects. To resolve this dilemma, scientists can utilize the placenta-on-chip technology to analyze drug transport pathways. For example, they can monitor whether common drugs like caffeine, pain relievers, or antibiotics cross the maternal-fetal barrier. Additionally, researchers can evaluate the potential toxicity of newly developed molecules in real-time. This active screening process will help pharmaceutical companies identify safe pregnancy-specific therapies. Ultimately, this approach will expand the list of approved medicines for expectant mothers, improving their quality of life. Furthermore, this technology minimizes the need for controversial animal testing. Because human and animal placentas differ, this human-cell-based platform offers far superior predictive safety data. As a result, India can lead the global transition toward ethical, precise preclinical drug evaluation. This advancement will ultimately protect millions of lives of mothers and babies.

Advancing Research on Pregnancy Complications

In addition to drug safety, this new microfluidic system accelerates critical research into major pregnancy complications. For instance, conditions like pre-eclampsia and fetal growth restriction pose serious risks, yet scientists poorly understand their mechanisms. These disorders often stem from early placental dysfunction and restricted blood flow. By using this placenta-on-chip technology, researchers can simulate abnormal placental development and study the underlying disease biology. Moreover, they can explore how maternal infections or environmental toxins alter barrier permeability. Because the device utilizes actual human cells, it provides a much more accurate representation of patient-specific responses than animal tissues. Consequently, clinicians can discover novel biomarkers to detect these complications early. Furthermore, the platform's simplified design means that research labs across India can easily manufacture and utilize it. This accessibility will likely spark widespread collaboration and speed up therapeutic discoveries. Ultimately, this indigenous development empowers local scientists to tackle pressing maternal health issues. By combining engineering excellence with reproductive biology, India is setting a new standard for maternal healthcare research globally. Thus, this technology will pave the way for highly personalized pregnancy care in the near future.

Frequently Asked Questions

Q1: Why is research on the human placenta so challenging for medical scientists?

Directly studying the placenta during pregnancy presents massive ethical and safety issues because experimental procedures could harm the developing baby. Therefore, researchers cannot test new drugs on pregnant women. Additionally, animal models fail to provide accurate clinical insights because animal placentas structurally and functionally differ from human ones. Consequently, the medical community lacks sufficient safety data regarding how most modern drugs interact with the maternal-fetal barrier.

Q2: How does the new Indian placenta-on-chip technology differ from existing international models?

Unlike many international organ-on-chip systems, the Indian platform utilizes a much simpler and highly robust acrylic design. This engineering choice eliminates the need for expensive, complex microfluidic equipment and continuous perfusion systems. Furthermore, this cost-effective design prevents drug adsorption and fluid leakage, which commonly disrupt traditional polydimethylsiloxane models. Consequently, diverse laboratories across India can easily manufacture, operate, and scale this device without needing specialized infrastructure.

Q3: Can this newly developed chip model help doctors study pregnancy disorders like gestational diabetes?

Yes, this advanced device can successfully replicate the physiological changes associated with gestational diabetes. Specifically, during validation trials, researchers exposed the human-relevant chip to hyperglycemic conditions to observe metabolic responses. The platform successfully simulated diabetic states by actively adjusting glucose transport and hormone secretion. Consequently, doctors can utilize this technology to investigate disease biology and safely evaluate how diabetic therapies impact the fetus.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. IIT Bombay scientists develop placenta-on-chip to aid foetal research - ETHealthworld


2. Bhide, A., Mukherjee, S., Ghosh, K., Majumder, A., & Modi, D. (2026). A Functional Placenta-On-Chip Model For Maternal\u2013Fetal Transport. Biofabrication, 18(3), ae7bc8.


3. Indian Council of Medical Research - National Institute for Research on Women's Health (ICMR-NIRWoH) & IIT Bombay. Indigenous Placenta-on-Chip Platform Technical Release (2026).